This year’s AAPS conference delivered strong scientific value and clear signals about where our industry is heading. Here are a few of the top trends shaping bioanalysis and biotherapeutic development:
The Expanding Role of LC and LC-MS in Surfactant and Excipient Evaluation
A recurring theme throughout the event was the need to modernize excipient and surfactant testing. There was considerable focus on how traditional methods often fall short, especially when dealing with polysorbate degradation, metal-catalyzed breakdown, and complex excipient interactions. As such, two notable insights came through in the discussions:
- Trace metal contaminants can accelerate PS80 degradation, requiring LC or LC-MS workflows for full characterization.
- Advanced chromatographic workflows—such as 2D-LC-CAD with online protein removal—are emerging as powerful tools to detect not just surfactant levels, but the full spectrum of their degradation products.
As high-concentration biologics become more common, surfactant stability and packaging-related risks will continue to rise in importance.
A Shift Toward Simplicity and Predictive Modeling in Immunogenicity & ADA Testing
Single-tier S/N ADA assays are gaining FDA acceptance, and computational models are helping predict ADA behavior earlier in development. Considerations include:
- Single-tier ADA assays using signal-to-noise metrics are gaining regulatory acceptance and provide a streamlined alternative to traditional multilevel workflows.
- Computational modeling is emerging as a tool for predicting ADA behavior and optimizing assay parameters early in development.
- As cell and gene therapies mature, ADAs to delivery vectors such as AAVs and LNPs must be considered during assay planning.
Collectively, these trends point toward more predictive, phase-appropriate ADA strategies.
CMC Strategy Matters More Than Ever
Analytical needs shift significantly from early-phase flexibility to late-phase rigor—especially for stability, integrity, and regulatory alignment. High-level sessions examined how analytical strategies must evolve through the biotherapeutic lifecycle. Early-phase flexibility gives way to late-phase rigor, with stability, structural integrity, and regulatory alignment becoming dominant concerns.
These discussions highlighted how interconnected analytical, formulation, and regulatory strategies have become, particularly for organizations planning long-term commercialization.
The conference overall offers a strong pulse on where the industry is heading. This year’s event provided meaningful insights that will influence how organizations design assays, plan programs, and prepare for future regulatory expectations.